- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| TRANSCODE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Mo | TransCode Therapeutics appoints Michel Janicot as development officer | 1 | Investing.com | ||
| 27.10. | Transcode Therapeutics ändert Bedingungen für Vorzugsaktien nach Aktionärszustimmung | 2 | Investing.com Deutsch | ||
| 27.10. | Transcode Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 14.10. | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.10. | TransCode Therapeutics, Inc.: TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO | 159 | PR Newswire | Safety primary endpoint achieved
Median treatment duration of 4 months with a range of 2 to 12 months and three patients remain on trial
RECIST data with... ► Artikel lesen | |
| 08.10. | TransCode Therapeutics Stock Jumps 21% On Polynoma Acquisition | 2 | RTTNews | ||
| 08.10. | TransCode Therapeutics stock soars after Polynoma acquisition | 3 | Investing.com | ||
| 08.10. | TransCode Therapeutics, Inc.: TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology ... | 171 | PR Newswire | TransCode acquires 100% of the issued and outstanding interests of Polynoma from CK Life Sciences
Concurrent equity investment of $25 Million from CK Life Sciences... ► Artikel lesen | |
| 03.10. | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.09. | Transcode Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 13.06. | Transcode Therapeutics, Inc. - 8-K, Current Report | 6 | SEC Filings | ||
| 28.05. | TransCode Therapeutics appoints RNA expert to advisory board | 9 | Investing.com | ||
| 28.05. | TransCode Therapeutics beruft RNA-Experten in den Beirat | 7 | Investing.com Deutsch | ||
| 08.05. | TransCode Therapeutics, Inc.: TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported | 256 | PR Newswire | 15 patients treated across four escalating dose levels of TTX-MC138
No significant safety or dose limiting toxicities reported
10 patients remain on study with... ► Artikel lesen | |
| 05.05. | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split | 347 | PR Newswire | BOSTON, May 5, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company committed to more effectively... ► Artikel lesen | |
| 02.05. | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces 1-for-28 Reverse Stock Split | 180 | PR Newswire | Split designed to achieve compliance with Nasdaq minimum bid price requirements
BOSTON, May 2, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ)... ► Artikel lesen | |
| 01.05. | TransCode Therapeutics, Inc.: TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer | 151 | PR Newswire | A total of 13 patients treated with four escalating doses of TTX-MC138
No significant safety or dose limiting toxicities reported
Two patients have so far maintained... ► Artikel lesen | |
| 27.03. | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138 | 247 | PR Newswire | First patient in Cohort four has been treated with TTX-MC138
Ten patients have been treated with TTX-MC138 at escalating dose levels
Additional patients being... ► Artikel lesen | |
| 21.03. | Pre-market Movers: Allurion Technologies, Impact BioMedical, Patriot National Bancorp, TransCode Therapeutics, DSS, Inc. | 773 | AFX News | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.10 A.M. ET).In the Green Allurion Technologies Inc. (ALUR) is up over 64% at... ► Artikel lesen | |
| 13.03. | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial | 316 | PR Newswire | Clinical trial Safety Review Committee (SRC) approved opening of Cohort 4 based on favorable safety data from the three patients comprising Cohort 3
No significant... ► Artikel lesen |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 88,25 | +0,34 % | BioNTech Aktie: Große Gewinne? - Bayer, Evotec, Hensoldt, Kontron und Rheinmetall im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| QIAGEN | 39,250 | +3,10 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| NOVAVAX | 5,562 | +1,04 % | Novavax bei Jefferies London: Strategischer Wandel hin zu Partnerschaften | ||
| PALATIN TECHNOLOGIES | 13,450 | 0,00 % | Palatin Technologies, Inc.: Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update | Significant progress on multiple fronts - obesity pipeline advancing towards the clinic, out-licensing collaboration, strengthened balance sheet, and reinstatement... ► Artikel lesen | |
| BRAIN BIOTECH | 3,350 | +9,48 % | EQS-PVR: BRAIN Biotech AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: BRAIN Biotech AG
BRAIN Biotech AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
20.10.2025 / 15:38 CET/CEST
Veröffentlichung... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer | SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,560 | +0,65 % | Inovio Pharmaceuticals stock price target raised to $6 by Piper Sandler | ||
| COSCIENS BIOPHARMA | 1,820 | +1,11 % | COSCIENS Biopharma Inc. Announces Leadership Change | TORONTO, ONTARIO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) ("COSCIENS" or the "Company"), a life science company focused on natural ingredients and pharmaceutical... ► Artikel lesen | |
| XOMA ROYALTY | 27,800 | -3,47 % | XOMA Royalty secures 87% of LAVA Therapeutics shares in tender offer | ||
| PHIO PHARMACEUTICALS | 1,240 | 0,00 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress | King of Prussia, Pennsylvania--(Newsfile Corp. - November 17, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its... ► Artikel lesen | |
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-Q, Quarterly Report | ||
| T2 BIOSYSTEMS | 0,250 | 0,00 % | NSE/A - T2 Biosystems, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| ORAGENICS | 0,960 | 0,00 % | Oragenics Q2 2025 Shareholder Update | Advancing Brain-First Recovery Platform Toward Clinical MilestonesPioneering Intranasal Therapeutics for Concussion SARASOTA, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American:... ► Artikel lesen | |
| LADRX | - | - | LadRx Corp - 8-K, Current Report | ||
| TENAX THERAPEUTICS | 2,770 | -100,00 % | This analyst loves Tenax Therapeutics |
TRANSCODE THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 8,420 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TRANSCODE THERAPEUTICS INC finden Sie auf Wallstreet Online.